Abstract
In general, the ICH Step 2* draft document on ’Safety Studies for Biotechnological Products’ captures the essence of a scientificallybased safety evaluation programme inclusive of interferons and interleukins.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson TD, Arceco R and Hayes TJ (1993a). Comparative toxicity and pathology associated with administration of recombinant HulL-1 alpha to animals. International Review of Experimental Pathology, 34A: 9–36.
Anderson TD, Hayes TJ, Powers GD et al. (1993b). Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. International Review of Experimental Pathology, 34A: 57–77.
Anari MR, Cribb AE and Renton KW (1995). The duration of induction and species influences the downregulation of cytochrome P450 by the interferon inducer polyinosinic acid-polycytidylic acid. Drug Metabolism and Disposition, 23: 536–541.
Cribb AE, Delaporte E, Kim SG, Novak RF and Renton KW (1994). Regulation of cytochrome P-450A and cytochrome P-4502E induction in the rat during the production of interferon alpha/beta. Journal of Pharmacology and Experimental Therapeutics, 268: 487–494.
Hall SS (1995). IL-12 at the crossroads [news]. Science, 268: 1432–1434.
Hayes TJ and Cavagnaro JA (1992). Progress and challenges in the preclinical assessment of cytokines. Toxicology Letters, 64/65: 291–297.
Hayes TJ and Ryffel B (1997). Safety considerations for recombinant protein therapy: introductory comments. Clinical Immunology and Immunopathology, 83:1–4.
Lotze M and Gately M (1996). Interleukin-12. Annals of the New York Academy of Science.
Mannering GJ and DeLoria LB (1986). The pharmacology and toxicology of the interferons; an overview. Annual Review of Pharmacology and Toxicology, 26: 455–515.
Parkinson A, Lasker J, Kramer MJ, Huang MT, Thomas PE, Ryan DE, Reik LM, Norman RL, Levin W and Conney AH (1982). Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metabolism and Disposition, 10: 579–585.
Renton KW and Knuckle LC (1990). Regulation of hepatic cytochrome P-450 during infectious disease. Canadian Journal of Physiology and Pharmacology, 68: 777–781.
Renton KW and Mannering GJ (1976). Depression of hepatic cytochrome P-450 dependent monooxygenase systems with administered interferon inducing agents. Biochemical and Biophysical Research Communications, 73: 343–348.
Ryffel B (1993). Cytokine induced pathology. International Review of Experimental Pathology, 34A and B.
Ryffel B (1997). Interleukin-12: Role of interferon-gamma in IL-12 adverse effects. Clinical Immunology and hnmunopathology, 83:18–20.
Siegel JP, Gerrard T, Cavagnaro J, Keegan P, Cohen RB and Zoon KA. (1995). Development of biological therapies for oncologic use. In De Vita VT, Hellman S and Rosenberg SA (eds.) Biologic Therapy of Cancer, 2nd edn. JB Lippincott Company, Philadelphia, pp. 879–890.
Sreevalasan T (1995). Biologic therapy with interferon-alpha and beta: preclinical studies. In De Vita VT, Hellman S and Rosenberg SA (eds.) Biologic Therapy of Cancer, 2nd edn. JB Lippincott Company, Philadelphia, pp.347–
Terrel J and Green JD (1993). Comparative pathology of recombinant murine interferon-gamma in mice and recombinant human interferon-gamma in cynomologous monkeys. International Review of Experimental Pathology, 34B: 73–101.
Trown PW, Wills RJ and Kamm JJ (1986). The preclinical development of Roferon-A. Cancer, 57: 1648–1656.
Tushinski RJ and Mule JJ (1995). Biology of cytokines: the interleukins. In De Vita VT, Hellman S and Rosenberg SA (eds.) Biologic Therapy of Cancer, 2nd edn. JB Lippincott Company, Philadelphia, pp. 87–102.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Cavagnaro, J.A., Anderson, T. (1998). Designing non-clinical safety evaluation programmes for interferons and interleukins: Past experiences and recommendations for future products. In: Griffiths, S.A., Lumley, C.E. (eds) Safety Evaluation of Biotechnologically-derived Pharmaceuticals. CMR International Workshop Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4876-4_13
Download citation
DOI: https://doi.org/10.1007/978-94-011-4876-4_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6043-1
Online ISBN: 978-94-011-4876-4
eBook Packages: Springer Book Archive